The Drug Launch That Took 45 Percent of an Agency With It

There are clients you win, clients you lose and clients that rearrange the furniture while they are still in the room. For JUICE Pharma Worldwide, that client was Biogen and that product was Aduhelm, the Alzheimer's medicine approved in 2021 amid argument, hope and an unusually loud public reckoning over evidence, price and access.

JUICE was one of several agencies working on the business. Aduhelm was a large account, and its soft launch did not become the history-making commercial debut once imagined. Medicare placed severe limits on coverage. The consequences traveled down the supply chain: from medicine maker to brand budget to agency payroll. JUICE's annual revenue fell from $33 million to $18 million in 2022. Headcount went from 107 to 60.

The arithmetic is blunt. One troubled launch coincided with a $15 million revenue decline and 47 fewer jobs. North America CEO Forrest King acknowledged that the agency had been swept into the larger Alzheimer's story. Every specialist business should linger over the admission. Expertise creates an advantage. A concentrated account can turn the same expertise into a trapdoor.

What breaks after the blockbuster

The first thing to fail was not JUICE's creative process. It was the commercial premise around the launch. Aduhelm entered a thicket of medical controversy and constrained reimbursement; the agency was exposed because the account represented a large piece of business. That distinction matters. A team can execute its assignment and still be punished by a market condition it cannot control.

JUICE's answer was neither a triumphant pivot nor a tidy turnaround montage. It protected what talent it could, hired Katya Petrova as chief business officer and Chris Ozanian as chief experience officer, and brought in Dawn Whitelaw to tighten project-management discipline. It also added three accounts: Fore Genomics, ADMA Biologics and Eye Pharma. The assignments ranged from rare-disease therapies to eye health and Foresite 360, a genetic-testing product for new parents.

Then it productized part of its thinking. JUICE Amp, launched in 2022, analyzes multiple data streams for clinical and influence patterns. A separate health e-commerce enablement platform extended the offer closer to transaction. Neither tool erased the concentration shock. Together with the new accounts, they showed what had changed: the agency was building more ways to be useful while becoming, in King's word, “choiceful” about new business.

The agency with a verb problem

Advertising briefs are famously fond of nouns: awareness, engagement, differentiation. Nouns photograph well in decks. Human behavior, unfortunately, arrives as verbs. Ask. Start. Continue. Switch. Remember. Talk. A behavior-led approach forces a team to choose one.

That distinction explains JUICE's emphasis on behavioral science and data. Research can expose where the journey gets sticky: a patient who postpones a conversation, a professional who cannot quickly retrieve the relevant evidence, a consumer who confuses one health claim with another. Creative strategy then has a defined job. It is not there to make the deck prettier. It must reduce a particular piece of friction without outrunning what the evidence can support.

This sounds tidy. The market is not. Pharmaceutical communication carries legal, medical and regulatory constraints that a sneaker campaign never meets. It also serves people with radically different levels of knowledge and power. An oncologist reading clinical material and a newly diagnosed patient searching on a phone may be considering the same therapy, but they are not having the same day.

The useful question is not, “Which channel are we missing?” It is, “Which decision are we helping?”A portable lesson from JUICE's positioning

One brand, two rooms

JUICE sells to pharmaceutical and healthcare brand teams. The work, however, lands with two broad constituencies: people living with a condition and the professionals involved in their care. Patient communications may need to turn fog into a question worth asking. Professional communications may need to turn a large body of evidence into a clear reason to investigate further. One side values recognition and plain language. The other expects precision and clinical utility.

A generalist agency can buy the same media and hire excellent designers. The specialist advantage is accumulated judgment: knowing when an elegant simplification becomes an unhelpful one, understanding the review path, and developing patient and professional messages that sound different without contradicting each other. JUICE's mix of brand strategy, healthcare promotion, market insight and digital execution is designed for that coordination.

There is a cost to specialization. The framework is strongest when the product has credible evidence, the intended behavior can be named and the organization can give strategy, medical review and creative development access to one another. It weakens when “behavioral science” becomes decoration for a decision already made, or when omnichannel means publishing the same asset everywhere. A method built to resolve friction cannot rescue a vague objective.

Omnichannel is a sequence, not a receipt

The agency's service range - print, web, mobile, social, content, analytics and emerging technology - could look like a very long shopping list. The smarter reading is sequential. A search result, a professional detail, a patient website and a follow-up email are not four isolated deliverables. They are four possible moments in one decision. Each should remember what the previous moment accomplished.

This is also where data earns a role more useful than applause. Big dashboards are good at announcing that something happened. A behavior-first campaign asks whether the right thing happened, for whom and at which step. Did people merely watch? Did they seek information? Did professionals return to the evidence? Did the content answer the question that had stalled them? The measurement plan follows the behavior map, rather than arriving after launch like a receipt.

Founded in 2002 by Lois Moran, Lynn Macrone and Forrest King, JUICE uses the familiar agency model: organizations buy strategy, creative development, campaign production and ongoing marketing support through projects or retained relationships. What clients are really purchasing is coordination under constraint. The competitive set includes network healthcare agencies with global scale, independent specialists with deep therapeutic experience, digital consultancies with technology muscle and in-house teams with intimate brand knowledge. JUICE's position is the independent specialist that tries to keep behavioral insight, creative craft and digital delivery in the same conversation.

A small idea with a long shadow

The best thing to copy from JUICE is not a house style or a channel plan. It is a habit of scale. Large healthcare brands encourage large language: transformation, disruption, ecosystem. Human beings still move in small increments. Someone notices a symptom. Someone saves a question. Someone reads one more paragraph. Someone raises a subject in an examination room.

Designing backward from that increment makes a campaign less theatrical and more accountable. It can also make the creative better. Once the next move is specific, the work no longer has to perform “engagement” in the abstract. It has something to dramatize, explain or make easier.

That is JUICE Pharma Worldwide's most persuasive place in the market. The company is not the medicine maker, the media owner or the software platform. It is the translator in the middle, trying to make technical evidence, regulated claims and ordinary life occupy the same frame. The name promises energy. The work begins with something quieter: noticing exactly where a person stopped.